These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3064 related articles for article (PubMed ID: 7477192)

  • 1. Tissue plasminogen activator for acute ischemic stroke.
    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
    N Engl J Med; 1995 Dec; 333(24):1581-7. PubMed ID: 7477192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
    Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
    Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
    Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
    Cucchiara B; Kasner SE; Tanne D; Levine SR; Demchuk A; Messe SR; Sansing L; Lees KR; Lyden P;
    Stroke; 2009 Sep; 40(9):3067-72. PubMed ID: 19608993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM; Albers GW; Madden KP; Hamilton S
    Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NXY-059 for acute ischemic stroke.
    Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
    N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.
    Chiu D; Krieger D; Villar-Cordova C; Kasner SE; Morgenstern LB; Bratina PL; Yatsu FM; Grotta JC
    Stroke; 1998 Jan; 29(1):18-22. PubMed ID: 9445322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
    Broderick JP; Palesch YY; Demchuk AM; Yeatts SD; Khatri P; Hill MD; Jauch EC; Jovin TG; Yan B; Silver FL; von Kummer R; Molina CA; Demaerschalk BM; Budzik R; Clark WM; Zaidat OO; Malisch TW; Goyal M; Schonewille WJ; Mazighi M; Engelter ST; Anderson C; Spilker J; Carrozzella J; Ryckborst KJ; Janis LS; Martin RH; Foster LD; Tomsick TA;
    N Engl J Med; 2013 Mar; 368(10):893-903. PubMed ID: 23390923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
    Haley EC; Brott TG; Sheppard GL; Barsan W; Broderick J; Marler JR; Kongable GL; Spilker J; Massey S; Hansen CA
    Stroke; 1993 Jul; 24(7):1000-4. PubMed ID: 8322373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endovascular treatment for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M; Sgoifo A; Ponzio M; Sterzi R; Boccardi E;
    N Engl J Med; 2013 Mar; 368(10):904-13. PubMed ID: 23387822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
    Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
    N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
    Qin Z; Chen L; Liu M; Tan H; Zheng L
    Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
    Haley EC; Levy DE; Brott TG; Sheppard GL; Wong MC; Kongable GL; Torner JC; Marler JR
    Stroke; 1992 May; 23(5):641-5. PubMed ID: 1579959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
    Ma H; Campbell BCV; Parsons MW; Churilov L; Levi CR; Hsu C; Kleinig TJ; Wijeratne T; Curtze S; Dewey HM; Miteff F; Tsai CH; Lee JT; Phan TG; Mahant N; Sun MC; Krause M; Sturm J; Grimley R; Chen CH; Hu CJ; Wong AA; Field D; Sun Y; Barber PA; Sabet A; Jannes J; Jeng JS; Clissold B; Markus R; Lin CH; Lien LM; Bladin CF; Christensen S; Yassi N; Sharma G; Bivard A; Desmond PM; Yan B; Mitchell PJ; Thijs V; Carey L; Meretoja A; Davis SM; Donnan GA;
    N Engl J Med; 2019 May; 380(19):1795-1803. PubMed ID: 31067369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
    Grotta J;
    Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 154.